Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes
Authors' conclusion
This study suggests long-term benefits of IT on diabetes-related outcomes. Furthermore, despite the use of immunosuppressive drugs following IT, we observed no significant increase in the risk of cancer. Altogether, these findings highlight a favorable risk-benefit ratio of IT in treating patients with unstable T1D.
Study context
- Population
- Patients with T1D: IT recipients from three IT clinical trials and propensity-matched T1D patients from the French SNDS claims databasematched cohorts
- Participants
- 61 / 610 / 45 / 45
- Exposure
- Islet transplantation vs matched T1D controls
- ITAn = 61
- ITA controlsn = 610reference
- IAKn = 45
- IAK controlsn = 45reference
- Outcome
- Composite of:
- Death
- Dialysis
- Amputation
- Nonfatal stroke
- Nonfatal MI
- Transient ischemic attack
- Follow-up
- Median >10 years
Methodological detailsmulticenter, propensity score matched
- Multicenter
- Propensity score matched
Main finding
As reported in the abstract
Composite outcome
Hazard ratio (95% CI)P value
ITAvs ITA controls
0.39(0.21–0.71)
P = 0.002IAKvs IAK controls
0.52(0.30–0.88)
P = 0.014Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Mortality (ITA)ITAvs ITA controls | 0.22 (0.09–0.54) | P < 0.001 | |
| Dialysis (IAK)IAKvs IAK controls | 0.19 (0.07–0.50) | P < 0.001 | |
| 0.050.21520Hazard ratio (log scale) |
Safety
- Both groups showed no significant changes in cancer risk
Original publication
Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes. Diabetes Care. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →